Category: Uncategorized

Ermium Therapeutics strengthen its leadership team with the recent appointment of Dr Hélène Asnagli as head of biology / pharmacology

Ermium Therapeutics strengthen its leadership team with the recent appointment of Dr Hélène Asnagli as head of biology / pharmacology

Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today the expansion of the Company management team with the appointment of Dr Hélène Asnagli as Head of Biology/Pharmacology.

Dr Asnagli brings strong expertise in non-clinical R&D for auto-immune diseases.

Share

Ermium Therapeutics to present promising preclinical data highlighting the therapeutic potential of Ermium immunomodulators for the treatment of systemic lupus erythematosus at the annual ACR Convergence 2022 conference

Ermium Therapeutics to present promising preclinical data highlighting the therapeutic potential of Ermium immunomodulators for the treatment of systemic lupus erythematosus at the annual ACR Convergence 2022 conference

Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today that Dr Annegret Van der Aa, CSO/CDO will be presenting promising preclinical data on Ermium immunomodulators for the treatment of systemic lupus erythematosus (SLE) and other type I interferon-driven diseases at the ACR Convergence 2022 conference to be held between November 10th – 14th in Philadelphia, US, and virtually.

Share

CXCR4 as a novel target in immunology: moving away from typical antagonists

Dr Annegret Van der Aa (CSO – CDO), Dr Kristof Van Emelen (Head of Medicinal Chemistry) and Dr Jean-Philip Herbeuval (Scientific founder) are co-author of “CXCR4 as a novel target in immunology: moving away from typical antagonists” published online in Future Drug Discovery (vol 4, n°2) – see link. This publication is at the cornerstone of Ermium CXCR4-specific immunomodulators and their uses in auto-immune diseases. It gathers scientists from Université Paris Cité, CNRS, University of Glasgow, and Ermium Therapeutics.

Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M

Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M

Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M to further advance breakthrough auto-immune disease therapeutics.

Share

Formation of a Scientific Advisory Board

Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today the expansion of the Company management team with the appointment of Dr Hélène Asnagli as Head of Biology/Pharmacology. Dr Asnagli brings strong expertise in non-clinical R&D for auto-immune diseases.